IDXX · Earnings call · 2026Q2T · Full report

Guidance and Outlook

IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 61 · Surprise 76 · No source text

IDEXX raised its 2026 revenue outlook to $4.700 billion-$4.745 billion, reflecting a $20 million operational improvement partially offset by the $15 million FX headwind. Full-year organic revenue growth is now expected at 8.5%-9.7%, including 9.5%-10.7% growth in Companion Animal Group Diagnostics recurring revenue. The company increased its EPS outlook to $14.69-$14.94, representing 13%-15% comparable growth, and expects 70-90 basis points of comparable operating-margin improvement. Management plans incremental commercial and R&D investments in the second half while expecting third-quarter reported operating margins of 32.5%-32.8%.

Key facts

• Updated full year revenue outlook is $4,700 million to $4,745 million.
• The updated full year overall organic revenue growth outlook is 8.5% to 9.7%.
• Updated organic CAG Diagnostics recurring revenue growth outlook is 9.5% to 10.7% for the full year, including approximately a 4% benefit for global net price realization.
• Updated full year EPS outlook is $14.69 to $14.94 per share, an increase of $0.14 per share at midpoint reflecting 13% to 15% comparable EPS growth.
• EPS outlook includes an increase of $0.05 per share related to share-based compensation benefits and a $0.05 headwind from updated foreign exchange rates.
• For the third quarter, IDEXX is planning organic revenue growth in line with the implied second half growth range and foreign currency impacts creating a 70 basis point headwind to reported revenues at rates outlined in the press release.

Impact estimates